Article information
Full text is only aviable in PDF
Bibliografía
[1.]
G.E. D'Alonzo, R.J. Barst, S.M. Ayres, E.H. Bergofsky, B.H. Brundage, K.M. Detre, et al.
Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.
Ann Intern Med, 115 (1991), pp. 343-349
[2.]
S. Rich, D.R. Dantzker, S.M. Ayres, E.H. Bergofsky, B.H. Brundage, K.M. Detre, et al.
Primary pulmonar hypertension. A national prospective study.
Ann Intern Med, 107 (1987), pp. 216-223
[3.]
N.F. Voelkel, R.M. Tuder.
Severe pulmonary hypertensive diseases: a perspective.
Eur Respir J, 14 (1999), pp. 1246-1250
[4.]
N.F. Voelkel, R.M. Tuder.
Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension.
Eur Respir J, 8 (1995), pp. 2129-2138
[5.]
S.D. Lee, K.R. Shroyer, N.E. Markham, C.D. Cool, N.F. Voelkel, R.M. Tuder.
Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension.
J Clin Invest, 101 (1998), pp. 927-934
[6.]
Z. Deng, J.H. Morse, S.L. Slager, N. Cuervo, K.J. Moore, G. Venetos, et al.
Family primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene.
Am J Hum Genet, 67 (2000), pp. 737-744
[7.]
K.B. Lane, R.D. Machado, M.W. Pauciulo, J.R. Thomson, J.A. Phillips, J.E. Loyd, et al.
Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension.
Nat Genet, 26 (2000), pp. 81-84
[8.]
W.C. Nichols, D.L. Koller, B. Slovis, T. Foroud, V.H. Terry, N.D. Arnold, et al.
Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-q32.
Nat Genet, 15 (1997), pp. 277-280
[9.]
J.H. Morse, A.C. Jones, R.J. Barst, S.E. Hodge, K.C. Wilhelmsen, T.G. Nygaard.
Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-32.
Circulation, 95 (1997), pp. 2603-2606
[10.]
J.R. Thomson, R.D. Machado, M.W. Pauciulo, N.V. Morgan, M. Humbert, G.C. Elliott, et al.
Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPRII, a receptor member of the TGF-beta family.
J Med Genet, 37 (2000), pp. 741-745
[11.]
H.I. Palevsky, B.L. Schloo, G.G. Pietra, K.T. Weber, J.S. Janicki, E. Rubin, et al.
Primary pulmonary hypertension. Vascular structure, morphometry, and responsiveness to vasodilator agents.
Circulation, 80 (1989), pp. 1207-1221
[12.]
Executive summary from the World Symposium on Primary Pulmonary Hypertension 1998. Co-sponsored by The World Health Organization. Disponible de la World Health Organization a través de Internet: http://www.who.int/ncd/cvd/pph.html.
[13.]
V. Fuster, P.M. Steele, W.D. Edwards, B.J. Gersh, M.D. McGoon, R.L. Frye.
Primary pulmonary hypertension: natural history and the importance of thrombosis.
Circulation, 70 (1984), pp. 580-587
[14.]
L.J. Rubin.
Primary pulmonary hypertension.
N Engl J Med, 336 (1997), pp. 111-117
[15.]
S. Rich, E. Kaufmann, P.S. Levy.
The effect of high doses of calcium- channel blockers on survival in primary pulmonary hypertension.
N Engl J Med, 327 (1992), pp. 76-81
[16.]
J. Partanen, M.S. Nieminen, K. Luomanmaki.
Death in a patient with primary pulmonary hypertension after 20 mg of nifedipine.
N Engl J Med, 329 (1993), pp. 812-813
[17.]
O. Sitbon, F. Brenot, A. Denjean, A. Bergeron, F. Parent, R. Azarian, et al.
Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin.
Am J Respir Crit Care Med, 151 (1995), pp. 384-389
[18.]
R.J. Barst, L.J. Rubin, W.A. Long, M.D. McGoon, S. Rich, D.B. Badesch, et al.
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group.
N Engl J Med, 334 (1996), pp. 296-302
[19.]
V.V. McLaughlin, D.E. Genthner, M.M. Panella, S. Rich.
Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.
N Engl J Med, 338 (1998), pp. 273-277
[20.]
J.V. Conte, S.P. Gaine, J.B. Orens, T. Harris, L.J. Rubin.
The influence of continuous intravenous prostacyclin therapy for primary pulmonary hypertension on the timing and outcome of transplantation.
J Heart Lung Transplant, 17 (1998), pp. 679-685
[21.]
M.M. Hoeper, M. Schwarze, S. Ehlerding, A. Adler-Schuermeyer, E. Spiekerkoetter, J. Niedermeyer, et al.
Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue.
N Engl J Med, 342 (2000), pp. 1866-1870
[22.]
N. Nagaya, M. Uematsu, Y. Okano, T. Satoh, S. Kyotani, F. Sakamaki, et al.
Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension.
J Am Coll Cardiol, 34 (1999), pp. 1188-1192
[23.]
Y. Katayama, T.W. Higenbottam, G. Cremona, S. Akamine, E.A. Demoncheaux, A.P. Smith, et al.
Minimizing the inhaled dose of NO with breath-by-breath delivery of spikes of concentrated gas.
Circulation, 98 (1998), pp. 2429-2432
[24.]
J. Weiman, R. Ullrich, J. Hromi, Y. Fujino, K.D. Bloch, W.M. Zapol.
Sildenafil (Viagra) is a selective pulmonary vasodilator in acute pulmonary hypertension in awake sheep [resumen].
Am J Respir Crit Care Med, 159 (1999), pp. A163
[25.]
S.J. Chen, Y.F. Chen, Q.C. Meng, J. Durand, V.S. Dicarlo, S. Oparil.
Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats.
J Appl Physiol, 79 (1995), pp. 2122-2131
[26.]
M.W. Geraci, B. Gao, D.C. Shepherd, M.D. Moore, J.Y. Westcott, K.A. Fagan, et al.
Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension.
J Clin Invest, 103 (1999), pp. 1509-1515
[27.]
A.I. Campbell, M.A. Kuliszewski, D.J. Stewart.
Cell-based gene transfer to the pulmonary vasculature: endothelial nitric oxide synthase overexpression inhibits monocrotaline-induced pulmonary hypertension.
Am J Respir Crit Care Med, 21 (1999), pp. 567-575
Copyright © 2001. Sociedad Española de Neumología y Cirugía Torácica
